In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis of novel N-(benzoylphenyl)-5-substituted-1
H-indole-2-carboxamides (compounds
8-
12,
15,
16,
18) and investigating their antihyperlipidemic activity using Triton WR-1339-induced hyperlipidemic rats as an
[...] Read more.
In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis of novel N-(benzoylphenyl)-5-substituted-1
H-indole-2-carboxamides (compounds
8-
12,
15,
16,
18) and investigating their antihyperlipidemic activity using Triton WR-1339-induced hyperlipidemic rats as an experimental model. Hyperlipidemia was developed by intraperitoneal injection of Triton WR-1339 (250 mg/kg body weight). The tested animals were divided into normal control (NCG), hyperlipidemic (HG), compound
8,
9,
15,
16,
18- and bezafibrate treated groups. At a dose of 15 mg/kg body weight, compounds
9,
16,
18 and bezafibrate (100 mg/kg) significantly (
p < 0.0001) reduced elevated plasma triglycerides levels after 12 h compared to the hyperlipidemic control group. However, only the group treated with compounds
9,
16 and
18 showed an obviously significant (
p < 0.001) reduction in plasma total cholesterol levels after 12 h compared to the hyperlipidemic control group. Moreover, high density lipoprotein-cholesterol levels were significantly (
p < 0.0001) increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for compounds
8 and
15 which revealed inactive. It is therefore reasonable to assume that compounds
9,
16 and
18 may have potential in the treatment of hyperlipidemia.
Full article
